Related by context. All words. (Click for frequent words.) 79 chemoradiotherapy 75 preoperative chemotherapy 74 adjuvant chemotherapy 74 neoadjuvant chemotherapy 73 adjuvant radiation 72 adjuvant therapy 72 neoadjuvant 72 postoperative chemotherapy 71 chemoradiation therapy 71 cytoreductive surgery 71 neoadjuvant therapy 71 Doxil ® 71 carboplatin paclitaxel 70 cytoreduction 70 adjuvant radiotherapy 70 TACE 70 pegylated liposomal doxorubicin 70 FOLFOX4 70 cisplatin 69 external beam radiotherapy 69 fluorouracil 69 gemcitabine 69 dacarbazine 69 brain metastases 69 neoadjuvant treatment 69 androgen deprivation 68 concurrent chemoradiation 68 EBRT 68 5FU 68 chemotherapy docetaxel 68 cisplatin chemotherapy 68 locoregional recurrence 68 docetaxel chemotherapy 68 FOLFIRI 68 lymphadenectomy 68 FOLFOX 68 chemotherapy regimens 68 chemoembolization 68 nab paclitaxel 68 chlorambucil 68 ABVD 67 ALND 67 gemcitabine chemotherapy 67 topotecan 67 metastatic renal cell carcinoma 67 mycophenolate mofetil 67 docetaxel 67 lymph node dissection 67 chemotherapy regimen 67 epirubicin 67 metastatic RCC 67 cystectomy 67 hepatic metastases 67 locoregional 67 cytotoxic chemotherapy 67 hormonal therapy 67 standard chemotherapy regimen 67 radiochemotherapy 67 debulking surgery 67 temozolomide 67 trastuzumab 67 axillary dissection 67 XELOX 67 adjuvant tamoxifen 67 dose cytarabine 67 androgen suppression 67 Fludara 67 paclitaxel carboplatin 67 tumor resection 67 bortezomib 66 mitoxantrone 66 radical nephrectomy 66 standard chemotherapy regimens 66 carboplatin 66 liver resection 66 pemetrexed 66 HER2 positive metastatic breast 66 gefitinib 66 distant metastases 66 tamoxifen therapy 66 eribulin 66 vinorelbine 66 plus dexamethasone 66 curative resection 66 placebo dexamethasone 66 colorectal liver metastases 66 gemcitabine Gemzar 66 capecitabine 66 5-FU/LV 66 decitabine 66 pneumonectomy 66 WBRT 66 pegylated interferon alfa 2b 66 cetuximab 66 liver metastases 66 stage IIIB 65 pCR 65 surgical debulking 65 platinum refractory 65 vandetanib 65 chemotherapeutic regimens 65 bevacizumab 65 androgen ablation 65 CHOP chemotherapy 65 heavily pretreated patients 65 peginterferon 65 pancreatic adenocarcinoma 65 idarubicin 65 radiation therapy 65 plus gemcitabine 65 temsirolimus 65 axillary node dissection 65 cyclophosphamide 65 intravenous bisphosphonates 65 Flu Cy 65 postoperative radiotherapy 65 operable breast cancer 65 Gemcitabine 65 colectomy 65 bronchial thermoplasty 65 sentinel node biopsy 65 unresectable 65 gemcitabine carboplatin 65 chemotherapy 64 estramustine 64 irinotecan chemotherapy 64 DMARDs 64 sunitinib 64 Adjuvant chemotherapy 64 lenalidomide dexamethasone 64 Neoadjuvant 64 zoledronic acid 64 FOLFOX6 64 ASCT 64 antithrombotic therapy 64 mCRC patients 64 patients evaluable 64 GnRH agonists 64 antiplatelet therapy 64 transurethral resection 64 APTIVUS r 64 radical prostatectomy 64 taxane therapy 64 melphalan prednisone 64 tumor recurrence 64 radiotherapy RT 64 oral clodronate 64 MGd 64 Taxotere ® 64 FOLPI 64 docetaxel Taxotere 64 recurrent NSCLC 64 sentinel lymph node biopsy 64 lung metastases 64 BEACOPP 64 tumor shrinkage 64 IV NSCLC 64 recurrent GBM 64 KRAS mutations occur 64 recurrent glioblastoma multiforme 64 imatinib 63 chemo radiotherapy 63 clinically localized prostate 63 relapsed ovarian cancer 63 DMARD 63 azacitidine 63 temozolomide TMZ 63 DMARD therapy 63 cytogenetic response 63 Cisplatin 63 DAPT 63 unresectable stage 63 nephrectomy 63 paroxysmal AF 63 rituximab 63 CR nPR 63 goserelin 63 ribavirin RBV 63 FluCAM 63 differentiated thyroid 63 refractory AML 63 dose dexamethasone 63 thromboembolic events 63 resectable 63 dacarbazine DTIC 63 sorafenib Nexavar ® 63 fludarabine 63 contralateral breast cancer 63 Folfox 63 warfarin therapy 63 axillary lymph node dissection 63 etoposide 63 intraperitoneal chemotherapy 63 SCCHN 63 pertuzumab 63 Irinotecan 63 renal tumors 63 localized prostate cancer 63 antibiotic prophylaxis 63 DOXIL 63 endometrial carcinoma 63 evaluable patients 63 dasatinib 63 trabectedin 63 azathioprine 63 CYPHER Stent 63 recurrent prostate cancer 63 nodal metastases 63 remission induction 63 infusional 5-FU/LV 63 TORISEL 63 complete remissions 63 5 fluorouracil 63 distant metastasis 63 octreotide LAR 63 biochemical recurrence 63 antiangiogenic therapy 63 EUS FNA 63 interferon alfa 2a 63 Allovectin 7 ® 63 underwent resection 63 salpingo oophorectomy 63 superficial bladder cancer 63 median PFS 63 erlotinib 63 advanced NSCLC 63 metastatic lung cancer 63 heavily pretreated 63 bone metastases 63 daunorubicin 62 exemestane 62 mapatumumab 62 aromatase inhibitor therapy 62 sorafenib Nexavar 62 free survival PFS 62 anastrozole 62 fallopian tube carcinoma 62 low dose cytarabine 62 KRAS status 62 corticosteroid therapy 62 lymph node involvement 62 cabazitaxel 62 relapsed SCLC 62 interferon alfa 62 non squamous NSCLC 62 paclitaxel Taxol R 62 adjuvant therapies 62 docetaxel prednisone 62 esophagectomy 62 recurrent metastatic 62 cytarabine 62 Trastuzumab 62 cranial radiation 62 5-fluorouracil/leucovorin 62 allogeneic stem cell 62 adriamycin 62 fibrinolytic therapy 62 clodronate 62 chemotherapies 62 follicular lymphoma FL 62 sorafenib 62 complete cytogenetic 62 breast conserving 62 lymph node removal 62 palliation 62 zalutumumab 62 5 FU 62 PegIFN RBV 62 tirofiban 62 biochemical relapse 62 methotrexate monotherapy 62 patients undergoing CABG 62 Platinol ® cisplatin 62 ixabepilone 62 Pemetrexed 62 Kaplan Meier analysis 62 CMV disease 62 anticoagulation therapy 62 pegylated interferon 62 NMIBC 62 partial nephrectomy 62 OPAXIO 62 cisplatin vinorelbine 62 low dose dexamethasone 62 FOLFIRINOX 62 eptifibatide 62 metastases 62 ACTEMRA TM 62 surgical excision 62 peg IFN 62 Peg IFN 62 mediastinoscopy 62 interferon ribavirin 62 iniparib 62 remission CR 62 radiofrequency ablation RFA 62 Surgical resection 62 metastatic disease 62 Radical prostatectomy 62 lobectomy 62 HER2 negative 62 SLNB 62 androgen deprivation therapy 62 bisphosphonate therapy 62 radical cystectomy 62 peritoneal cancer 61 nadolol 61 bevacizumab Avastin 61 medically inoperable 61 peg interferon 61 chemotherapy cisplatin 61 parathyroidectomy 61 mitomycin 61 grade gliomas 61 RECIST criteria 61 methotrexate therapy 61 TTF Therapy 61 sustained virologic response 61 fondaparinux 61 endarterectomy 61 stent implantation 61 epirubicin cyclophosphamide 61 breast carcinoma 61 bendamustine 61 oblimersen 61 revascularization procedures 61 capecitabine Xeloda 61 comparator arm 61 paclitaxel chemotherapy 61 alteplase 61 abciximab 61 metastatic prostate cancer 61 intraperitoneal therapy 61 Free Survival PFS 61 fluoropyrimidine 61 imatinib therapy 61 paclitaxel eluting stents 61 radiation chemoradiation 61 thromboprophylaxis 61 Torisel 61 receiving VICTRELIS 61 pamidronate 61 tamsulosin 61 oral diclofenac 61 basal cell carcinoma BCC 61 Lenalidomide 61 NSCLC 61 histologically confirmed 61 stage IIIb IV 61 malignant pleural mesothelioma 61 mcg albinterferon alfa 2b 61 allogeneic SCT 61 overlapping toxicities 61 interferon therapy 61 pelvic lymphadenectomy 61 liposomal doxorubicin 61 contralateral breast 61 endocrine therapy 61 radiation therapy SBRT 61 cytogenetic responses 61 cediranib 61 idraparinux 61 Taxotere 61 mg kg dose 61 fibrinolysis 61 letrozole 61 ELOXATIN 61 imipenem 61 advanced adenomas 61 ALA PDT 61 evaluable 61 unfractionated heparin 61 tenecteplase 61 abiraterone acetate 61 HER2 positive breast cancer 61 biologic therapy 61 therapeutic regimens 61 Amrubicin 61 preoperative radiotherapy 61 trials RCTs 61 β blockers 61 nonmelanoma skin cancers 61 CIMZIA TM 61 beam radiotherapy 61 erlotinib Tarceva ® 61 hormonal therapies 61 adrenalectomy 60 SLN biopsy 60 cyclophosphamide methotrexate 60 EFAPROXYN 60 prostatectomy 60 paclitaxel 60 peginterferon alfa 2a 60 axitinib 60 Combination therapy 60 flutamide 60 biologic DMARD 60 multimodality therapy 60 FOLFIRI alone 60 gefitinib Iressa 60 HSCT 60 Toxicities 60 liver metastasis 60 alfa 2a 60 interferon alfa 2b 60 radiotherapy 60 revascularization 60 reinfarction 60 nonmetastatic 60 melphalan 60 Bevacizumab 60 CIMZIA ™ 60 Velcade bortezomib 60 metastatic malignant 60 sustained virological response 60 infusional 60 Erlotinib 60 TNF inhibitor 60 androgen blockade 60 intravesical therapy 60 progression TTP 60 soft tissue sarcomas 60 AGILECT R 60 symptomatic VTE 60 cytogenetic abnormalities 60 care regimens CCR 60 mitomycin C 60 thrombolytic therapy 60 colorectal cancer liver metastases 60 adjuvant cisplatin 60 perioperative morbidity 60 tamoxifen 60 EGFR TKI 60 composite endpoint 60 follicular lymphoma 60 virological response 60 doxorubicin 60 postintervention 60 thoracoscopic lobectomy 60 dosage regimens 60 mitoxantrone chemotherapy 60 mRCC 60 metastatic colorectal cancer 60 CA4P 60 relapsed MM 60 anthracycline taxane 60 bevacizumab Avastin ® 60 intestinal metaplasia 60 teriflunomide 60 neo adjuvant 60 telaprevir dosed 60 hepatectomy 60 Bortezomib 60 ischemic cardiomyopathy 60 MACCE 60 cytotoxic therapy 60 Xelox 60 squamous histology 60 complete cytogenetic response 60 RECIST Response Evaluation Criteria 60 PSADT 60 nonoperative 60 Thal Dex 60 advanced hepatocellular carcinoma 60 neoadjuvant radiation 60 micrometastases 60 Capecitabine 60 postoperative complication 60 CABG 60 dose escalation 60 decompressive surgery 60 taxane chemotherapy 60 sleeve lobectomy 60 metastatic castration resistant 60 hematologic toxicity 60 PSA nadir 60 NSTE ACS 60 dual antiplatelet therapy 60 GISTs 60 invasive bladder 60 subgroup analyzes 60 paclitaxel Taxol 60 metastatic malignant melanoma 60 bone metastasis 60 indolent NHL 60 sunitinib malate 60 virologic failure 60 HNSCC 60 recurrences 60 metastatic GIST 60 antihypertensive therapy 60 Tavocept 60 peritoneal carcinomatosis 60 pT2 60 ICD implantation 60 bivalirudin 60 Gliadel Wafer 60 trabeculectomy 60 beta blocker therapy 60 paclitaxel Taxol ® 60 Vectibix monotherapy 60 Pegylated Interferon 60 epithelial ovarian cancer 60 splenectomized patients 60 nephron sparing surgery 60 gemcitabine cisplatin 60 NovoTTF 60 rituximab Rituxan 60 prostate cancer CRPC 60 metastatic squamous cell carcinoma 60 cancer mCRC 60 CR CRu 60 resected 60 APTIVUS R 60 doxorubicin HCl liposome injection 60 cinacalcet 60 cisplatin gemcitabine 60 antidepressant therapy 60 intra arterial chemotherapy 59 plus ribavirin 59 HER2 positive tumors 59 endosonography 59 TroVax ® 59 CANCIDAS 59 docetaxel Taxotere ® 59 recurrent VTE 59 monotherapy 59 dacarbazine chemotherapy 59 resection 59 Elitek 59 bladder cancers 59 pegylated interferon alfa 59 VcMP 59 transarterial chemoembolization 59 severe neutropenia 59 randomized trials 59 Fludarabine 59 cyclophosphamide chemotherapy 59 infliximab 59 doxorubicin docetaxel 59 Ceplene/IL-2 59 Cyclophosphamide 59 VIDAZA 59 enzastaurin 59 liver transplant recipients 59 invasive lobular carcinoma 59 fulvestrant 59 relapsed refractory 59 ritonavir boosted 59 nonsmall cell lung cancer 59 receiving highly emetogenic 59 ovarian carcinoma 59 carotid stenosis 59 prostate cancer CaP 59 RTOG 59 lenalidomide Revlimid R 59 folinic acid 59 chemotherapeutic agents 59 malignant lesions 59 Taxotere R 59 relapsed CLL 59 pazopanib 59 perioperative mortality 59 Induction Chemotherapy 59 alkylating agent 59 GP IIb IIIa inhibitors 59 trastuzumab Herceptin ® 59 HIPEC 59 taxanes 59 ximelagatran 59 viral kinetics 59 octreotide 59 erlotinib Tarceva 59 dose melphalan 59 Herceptin trastuzumab 59 CCyR 59 STEMI patients 59 locoregional disease 59 anthracyclines 59 gastrectomy 59 doxorubicin cyclophosphamide 59 cilengitide 59 elective PCI 59 hydroxychloroquine 59 therapy IMRT 59 Metastatic Breast Cancer 59 TURP 59 node dissection 59 pregabalin 59 papillary renal cell carcinoma 59 HBeAg seroconversion 59 refractory multiple myeloma 59 iniparib BSI 59 5 Fluorouracil 59 oral allopurinol 59 cytoreductive nephrectomy 59 leukemia AML 59 lymph node metastases 59 neurologic progression 59 Platinol 59 afatinib 59 NATRECOR R 59 leucovorin 59 recurrent glioblastoma 59 antimicrobial prophylaxis 59 ribavirin therapy 59 oncologic outcomes 59 SBRT 59 underwent surgical resection 59 aflibercept 59 androgen suppression therapy 59 sirolimus eluting stents 59 resistant ovarian cancer 59 MabCampath 59 stage IIIB IV 59 thalidomide Thalomid 59 Pegasys plus Copegus 59 adalimumab 59 Median progression 59 oophorectomy 59 definite stent thrombosis 59 ER CHOP 59 YONDELIS 59 nonoperative treatment 59 endoscopic resection 59 trans retinoic acid 59 serous ovarian cancer 59 radiotherapy SBRT 59 iodixanol 59 Gefitinib 59 Median survival 59 oral Xeloda 59 endocrine therapies 59 Hepatocellular Carcinoma HCC 59 ipsilateral stroke 59 Bezielle 59 VFEND 59 abatacept 59 oral rivaroxaban 59 clopidogrel 59 NATRECOR ® 59 radical prostatectomy RP 59 5 FU leucovorin 59 coronary revascularization 59 Cetuximab 59 LMWH 59 adecatumumab 59 perioperative complications 59 lenalidomide 59 bolus dose 59 IIIa inhibitor 59 coinfected patients 59 relapsing multiple sclerosis 59 pancreatic NET 59 HBeAg positive patients 59 darunavir ritonavir 59 levosimendan 59 diagnosed multiple myeloma 59 imatinib Gleevec 59 Gemzar ® 59 plus prednisone 59 Metastatic Prostate Cancer 59 fallopian tube cancers 59 GnRH agonist 59 prostate cancer HRPC 59 immunomodulatory therapy 59 HCV SPRINT 59 hepatocellular carcinomas 59 postoperative morbidity 59 abacavir lamivudine 59 baseline LDH 59 evaluable subjects 59 grade glioma 59 secondary efficacy endpoints 59 Paraplatin ® 59 thyroid nodules 59 AVODART 59 subtrochanteric 59 operable pancreatic cancer 59 pomalidomide 59 pyridostigmine 59 galiximab 59 undergone radical prostatectomy 59 Zevalin consolidation 59 sirolimus eluting stent 59 DOXIL ® 59 recurrent malignant glioma 59 severe exacerbations 59 PREZISTA r 59 immunosuppressive agents 59 amoxicillin clavulanate 59 rFVIIa 59 clopidogrel Plavix 59 biliary tract cancer 59 grade cervical intraepithelial 58 Docetaxel 58 prostate carcinoma 58 dexamethasone 58 HGS# 58 urothelial carcinoma 58 palifosfamide 58 Fludara ® 58 variceal hemorrhage 58 tocilizumab 58 Platinol ® 58 resections 58 aldosterone antagonists 58 carcinoma 58 colorectal adenoma 58 febrile neutropenia 58 perioperatively 58 Cytoxan 58 TEAEs 58 VELCADE melphalan 58 paclitaxel cisplatin 58 thyroidectomy 58 ALT flares 58 8mg/kg 58 #F FDG PET 58 virologic response 58 conventional angiography 58 sarcomatoid 58 Halaven 58 Mitoxantrone 58 metastatic kidney 58 relapsed refractory multiple myeloma 58 chemotherapeutic regimen 58 nonmetastatic prostate cancer 58 adenoma recurrence 58 squamous cell carcinoma SCC 58 relapsed multiple myeloma 58 adjuvant hormonal therapy 58 salmeterol fluticasone 58 glioblastoma multiforme GBM 58 Response Evaluation Criteria 58 nonresponders 58 bleomycin 58 partial remissions 58 dexamethasone Decadron 58 completely resected 58 Hormone Refractory Prostate Cancer 58 pain palliation 58 allopurinol 58 seminoma 58 metastatic lesions 58 Anthracycline 58 adenotonsillectomy 58 K ras mutations 58 FDG-PET/CT 58 intravenous cyclophosphamide 58 oral anticoagulation 58 clopidogrel pretreatment 58 relapsing MS 58 invasive candidiasis 58 enoxaparin 58 H. pylori eradication 58 tumor histology 58 micafungin 58 postoperative mortality 58 systemic ALCL 58 IFN beta 58 HER2 overexpression 58 breast irradiation 58 CsA 58 irinotecan doxorubicin oxaliplatin paclitaxel 58 PASI scores 58 catheter angiography 58 adenomatous polyps 58 lipid lowering therapy 58 TYKERB 58 chemotherapy gemcitabine 58 HRPC 58 myelosuppressive 58 non metastatic osteosarcoma 58 tiotropium 58 metastatic CRC 58 periprocedural 58 metastatic colorectal 58 TAXOTERE R 58 Oxaliplatin 58 prior chemotherapy regimens 58 APTIVUS 58 laryngectomy 58 Castration Resistant Prostate Cancer 58 oxycodone CR 58 tumor regressions 58 metastatic HRPC 58 KRAS wild 58 vertebral fracture 58 invasive coronary angiography 58 unstable angina UA 58 refractory CLL 58 paragangliomas 58 Proxinium TM 58 tipranavir ritonavir 58 TURBT 58 hyperthermia therapy 58 Doxil 58 irbesartan 58 adenoidectomy 58 bosentan 58 uric acid lowering 58 concurrent chemoradiotherapy 58 unresectable tumors 58 hypofractionated 58 surrogate endpoint 58 postoperative atrial fibrillation 58 EGFR inhibitors 58 rt PA 58 FDG PET 58 microwave hyperthermia 58 sipuleucel T 58 prognostic factors 58 virological failure 58 OPCAB 58 FOLFOX4 alone 58 Revlimid lenalidomide 58 anti angiogenic agents 58 BRCA2 mutation carriers 58 TNF antagonist 58 cranial irradiation 58 leiomyosarcoma 58 CYT# potent vascular disrupting 58 icatibant 58 glycoprotein IIb IIIa inhibitors 58 neoadjuvant chemoradiotherapy 58 TEMODAL 58 dose titration 58 stenting 58 NRTIs 58 epithelial tumors 58 glargine 58 NCCTG N# 58 F FDG PET 58 chronic GVHD 58 nonfatal MI 58 CTAP# Capsules 58 unfractionated heparin UFH 58 OncoVEX GM CSF 58 Peginterferon 58 reperfusion therapy 58 docetaxel Taxotere R 58 anthracycline 58 postsurgical 58 extrapleural pneumonectomy 58 Imprime PGG 58 ibandronate 58 eplerenone 58 antiarrhythmic drug 58 desvenlafaxine succinate 58 ependymoma 58 RF ablation 58 recurrent ovarian cancer 58 intralesional 58 dalteparin 58 paricalcitol 58 methotrexate MTX 58 dose regimens 58 Mitomycin C 58 Metastatic 58 infliximab monotherapy 58 discontinuations due 58 sirolimus 58 weekly subcutaneous injections 58 chronic lymphocytic leukemia CLL 58 BR.# 58 metastatic colorectal carcinoma 58 localized renal 58 cyclophosphamide doxorubicin vincristine 58 endometrial hyperplasia 58 tenofovir emtricitabine 58 follicular lymphomas 58 % CI #.#-#.# [003] 58 metastatic breast cancer 58 binary restenosis 58 castration resistant prostate cancer 58 #Gy 58 thrombolytic agents 57 pegylated interferon alfa 2a 57 opioid analgesia 57 intravitreal injections 57 reoperation 57 achieved sustained virologic 57 Acute Myeloid Leukaemia AML 57 contrast induced nephropathy 57 follicular non 57 indolent lymphomas 57 symptomatic paroxysmal AF 57 EGFR mutations 57 4mg/kg 57 Hodgkin lymphoma HL 57 genotypic resistance 57 CAELYX 57 posaconazole 57 antitumor effect 57 infliximab Remicade 57 hepatic resection 57 P = .# 57 bicalutamide 57 Natalizumab 57 advanced adenoma 57 oral Hycamtin 57 metastatic bladder 57 malignant neoplasms 57 CLL SLL 57 ZACTIMA 57 lumpectomy 57 mTOR inhibitors 57 thrombotic complications 57 systemic corticosteroid 57 irinotecan 57 platelet inhibitor 57 vertebroplasty 57 ARB telmisartan 57 Radiofrequency ablation 57 Navelbine 57 Neulasta ® 57 fibrinolytic 57 Fulvestrant 57 mycophenolate mofetil MMF 57 Metastatic Colorectal Cancer 57 oxaliplatin 57 advanced unresectable 57 timepoints 57 ELACYT 57 medullary thyroid cancer 57 interferon gamma 1b 57 morphometric vertebral fractures 57 prostate biopsy 57 tapentadol ER 57 certolizumab 57 elotuzumab 57 achieved ACR# 57 histologic subtype 57 pancreatectomy 57 tumor regression 57 eribulin mesylate 57 refractory NSCLC 57 invasive aspergillosis 57 hemorrhagic complications 57 fluorouracil leucovorin 57 hepatocellular carcinoma 57 KRAS mutant tumors 57 #mg BID [001] 57 palliative radiotherapy 57 Percutaneous Coronary Intervention 57 relapsed AML 57 arsenic trioxide 57 alpha interferons 57 intravesical 57 gemcitabine Gemzar ® 57 DLBCL 57 carcinomas 57 panobinostat 57 hormone receptor positive 57 CTEPH 57 chemotherapy FOLFOX 57 segmentectomy 57 thoracotomy 57 metastatic pancreatic 57 duplex ultrasonography 57 FOLFOX chemotherapy 57 bronchogenic carcinoma 57 letrozole Femara 57 HGS ETR1 57 Sentinel node biopsy 57 FOLPI regimen 57 APTIVUS ritonavir 57 prostate cancer PCa 57 HuMax EGFr 57 insulin detemir 57 LHRH agonists 57 solifenacin 57 gastroesophageal junction 57 BoNTA 57 renal insufficiency 57 MRgFUS 57 follicular NHL 57 Vicinium TM 57 ARIMIDEX 57 TMP SMX 57 aromatase inhibitor 57 mg/m2 dose 57 Adjuvant therapy 57 pegylated interferon alpha 57 LHRH analogues 57 transarterial 57 relapsed myeloma 57 aspirin clopidogrel 57 repigmentation 57 BRCA mutation carriers 57 antiarrhythmic drugs 57 gout flares 57 COPAXONE R 57 vincristine doxorubicin 57 lapatinib Tykerb 57 nonrandomized 57 cholecystectomy 57 thalidomide dexamethasone